CORIX BIOSCIENCE INC

As of September 30, 2017, CORIX BIOSCIENCE INC carries a market capitalization of 20.65M, placing it among publicly traded companies globally. Its enterprise value stands at 20.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2017, CORIX BIOSCIENCE INC has 20.65M shares outstanding.

These figures are as of September 30, 2017.

As of September 30, 2017, CORIX BIOSCIENCE INC maintains a current ratio of 5.11, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.41, indicating moderate leverage, while an interest coverage ratio of -2.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2017, CORIX BIOSCIENCE INC posted a negative return on equity (ROE) of -142.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -68.82, reflecting losses generated across the asset base.

As of the close on September 10, 2026, CORIX BIOSCIENCE INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.11.

These figures cover the twelve months ended September 30, 2017. EBITDA reached -857,119.00, while operating income came in at -905,733.00.

As of September 30, 2017, CORIX BIOSCIENCE INC holds 360,871.00 in cash and equivalents against 50,026.00 in total debt, resulting in a net debt position of -310,845.00. Total book value stands at 3.56M, with working capital of 3.23M providing operational flexibility.

CORIX BIOSCIENCE INC produced -3.13M in operating cash flow over the twelve months ended September 30, 2017. After subtracting 520.00 in capital expenditures, free cash flow totaled -3.13M - equivalent to -0.21 per share.

These figures cover the twelve months ended September 30, 2017. Free cash flow yield is negative at -21.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CORIX BIOSCIENCE INC shareholders.

CORIX BIOSCIENCE INC's most recent stock split took place on June 10, 2015 with a 1000:1 split ratio.